Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research
18 10월 2023 - 9:31PM
Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the
“Company”), an agricultural bioscience company, today announced
that the Company has exercised its option to finalize an exclusive
global, commercial license to advanced omega-3 production
technology from U.K.-based Rothamsted Research Limited
(“Rothamsted”). In 2020, Yield10 signed an exclusive collaboration
agreement with Rothamsted to support Rothamsted’s Flagship Program
to develop omega-3 oils in Camelina sativa (“Camelina”). As part of
the collaboration agreement, Yield10 received an exclusive option
to sign a global, exclusive license agreement for the technology.
The technology developed by Rothamsted enables the sustainable,
plant-based production of omega-3 nutritional oils in Camelina.
Over the last decade, the Rothamsted team, led by Professor
Johnathan Napier, Ph.D., Science Director, has demonstrated the
production of omega-3 oils in Camelina seed and conducted
evaluations of the oils in salmon feeding and human clinical
studies to demonstrate lipid lowering effects. Omega-3 oils are
essential for human nutrition and have demonstrated benefits in
heart health.
“Our decision to exercise the exclusive global option to the
omega-3 production technology with Rothamsted underscores our
belief that there will be significant market opportunities for the
omega-3 oil profiles that can be produced using Camelina as a
platform crop,” said Oliver Peoples, Ph.D., President and Chief
Executive Officer of Yield10 Bioscience. “The Rothamsted team has
advanced the omega-3 Camelina technology to where it is ready to
begin commercialization. We are also planning improvements in the
varieties through the deployment of our herbicide tolerance and
performance traits. Commercially, we are on a promising path to
commercializing elite omega-3 varieties of Camelina that combine
good agronomics in the field while also producing high-value,
high-purity omega-3 oils possessing very attractive economics.”
The potential market opportunity for omega-3 fatty acids
produced in Camelina includes use in pharmaceutical (ethyl-EPA)
products, dietary supplements, and food and feed ingredients.
Currently, the primary source of the essential fatty acids EPA
(eicosapentaenoic acid) and DHA (docosahexaenoic acid) is
ocean-caught fish, where omega-3 oil produced from anchovy harvest
is the industry benchmark. Over the last few years, there has been
increasing pressure on the supply of omega-3 oil due to
over-fishing. In 2023, Peru, which produces 20% of the global fish
oil supply, canceled its first season anchovy harvest due to a lack
of mature fish. Producing omega-3 fatty acids in Camelina may
represent a way to enable a predictable supply of high-quality
omega-3 oils to meet the global demand for EPA and DHA.
Under the collaboration with Yield10, additional intellectual
property has been developed by Rothamsted for next generation
omega-3 Camelina varieties. However, in response to customer
interest, Yield10 has elected to prioritize the current EPA8
omega-3 Camelina as the initial profile for commercialization. In
spring 2023, Yield10 planted omega-3 (EPA) Camelina at acre-scale
in the United States to begin the ramp-up of seed inventory for
future planting as well as to produce oil for use in business
development activities. The seed yield, oil content and oil
composition of the EPA8 Camelina variety have thus far met the
Company’s expectations for performance, setting the stage for
advanced development and possible future market introduction.
Yield10 plans to conduct further seed scale-up of EPA8 Camelina in
contra season in South America this winter. In the third quarter of
2023, Yield10 submitted a Request for Status Review (“RSR”) for
EPA8 Camelina to USDA-APHIS Biotechnology Regulatory Services under
the Sustainable, Ecological, Consistent, Uniform, Responsible,
Efficient (SECURE) Rule. A favorable review under the SECURE Rule
would allow the crop to be grown at large scale in the United
States.
Yield10 and Rothamsted are also pursuing commercial development
of Camelina to produce omega-3 oil containing both EPA and DHA
fatty acids as a sustainable alternative to oil obtained from
ocean-harvested fish, which serves as an essential ingredient for
fish feed used in aquaculture, including the farming of Atlantic
salmon.
About the EPA component of Omega-3 oil EPA is a
polyunsaturated fat (PUFA) that is primarily supplied in the human
diet by the consumption of oily fish such as salmon, anchovies, and
mackerel. Fish obtain EPA through the consumption of algae.
Clinical studies have shown that EPA is beneficial to humans as it
lowers triglycerides and reduces low-density lipoprotein (LDL)
cholesterol in the blood with beneficial cardiovascular effects.
Using Camelina to produce EPA may represent a way to produce this
beneficial ingredient without relying on the harvest of ocean fish.
Several commercial products containing EPA fatty acids or their
derivatives are available on the market, including pharmaceuticals,
nutritional supplements, and animal feed.
About Yield10 Bioscience
Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an
agricultural bioscience company that is leveraging advanced
genetics to develop the oilseed Camelina sativa ("Camelina") as a
platform crop for large-scale production of sustainable seed
products. These seed products include feedstock oils for renewable
diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA)
oils for pharmaceutical, nutraceutical and aquafeed applications;
and, in the future, PHA bioplastics for use as biodegradable
bioplastics. Our commercial plan is based on establishing a grain
contracting business leveraging our proprietary elite Camelina seed
varieties, focusing on the growing demand for low-carbon intensity
feedstock oil for biofuels and omega-3 oils for nutritional
applications. Yield10 is headquartered in Woburn, MA and has a
Canadian subsidiary, Yield10 Oilseeds Inc., located in Saskatoon,
Canada.
For more information about the Company, please
visit www.yield10bio.com, or follow the Company on X
(formerly Twitter), Facebook and LinkedIn.
(YTEN-G)
Safe Harbor for
Forward-Looking Statements
This press release contains forward-looking statements, which
are made pursuant to the safe harbor provisions of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, the completion of the global commercial license to the
omega-3 production technology, the development of EPA and EPA+DHA
Camelina and the performance and production capacity of the omega-3
production technology, that the pending RSR will be approved by
USDA-APHIS, the potential for large-scale production of EPA8
Camelina, the future commercialization, potential market
opportunity, economic viability and further development of the
omega-3 varieties of Camelina and the omega-3 oils produced
therefrom, and the potential for the omega-3 production technology
to provide sustainable alternatives to existing means of omega-3
oil production, constitute forward-looking
statements. Such forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results to
differ materially from those anticipated, including, but not
limited to, the risks and uncertainties detailed in Yield10
Bioscience's filings with the Securities and Exchange Commission.
Yield10 assumes no obligation to update any forward-looking
information contained in this press release or with respect to the
matters described herein.
Contacts: Yield10 Bioscience:Lynne H. Brum,
(617) 682-4693, LBrum@yield10bio.com
Investor Relations: Bret Shapiro, (561) 479-8566,
brets@coreir.comManaging Director, CORE IR
Media Inquiries: Eric Fischgrund, eric@fischtankpr.com FischTank
PR
Yield10 Bioscience (NASDAQ:YTEN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Yield10 Bioscience (NASDAQ:YTEN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024